Chinese pharmaceutical raw materials needs a new environment

The use of high-tech, and further optimize the production process of traditional bulk drugs, bulk drug substance to improve the technical content.2011 World Conference of Pharmaceutical API China (Shanghai) Exhibition CPHI has been in the "hot and cold" atmosphere in the end. Cold is the bulk drug raw material prices remain at low levels or even another record low, China's domestic demand for raw materials, drug companies have reduced the number of participants; hot, although the market demand is relatively flat, but the enthusiasm of foreign exhibitors generally high.API prices are low, are all due to overcapacity and fierce competition under the supply and demand imbalances, and the enthusiasm of foreign exhibitors, it is imminent or has already fallen into the trough of a new round of market purchases attracted the favorable opportunity. "Hot and cold," the market, another reminder of the local pharmaceutical companies, international development of the API need to develop new ideas and philosophy, reason to seek a new way."Two high and one left" the old mode of production and operation of bulk drugs, has been shrouded in contradiction of the market environment: one side is the raw material medicine, "Made in China" sound more and more influence, on the other side, China's raw material drug production pollute the environment voice has not weakened; side of the chemical raw material prices and rising production costs, manpower and other financial and business management costs continue to increase, on the other side, resveratrol anti-drug prices of raw materials and stumble their way endlessly, even below cost price; side is the capacity surplus, the price war intensified, the other side, foreign pharmaceutical companies in the use of "anti-dumping, countervailing," the barriers to trade protectionism in the name of manufacture, it is also enjoying the benefits of cheap Chinese medicine raw materials procurement.Degree of internationalization of Chinese medicine raw materials increased, should not merely in quantity, but should be more reflected in the quality. "The international" does not mean "Towards a first-class", if the raw material drug production technology and quality standards compliance is only a low level, plant extracts the production process of environmental and security system is only a low level or transient compliance, then the API China international brand marketing is still way off.For example, efforts to break through the VC step fermentation and enzymatic 7-ACA step in the new process to obtain low-cost, low power and low-pollution advantages of the multiple production; high value-added products to increase the proportion of exports of bulk drugs, consolidation of product processing chain extension of benefits; than the super- international high-end market product quality standards, the initiative to improve product quality control standards, the formation of bulk drugs export advantage at competitive prices, reflecting the pharmaceutical companies take social responsibility, environmental protection and safety, drug raw materials prices hit China's brand influence."Two high and one left" new model will facilitate pharmaceutical raw materials companies have more independent intellectual property rights and better quality assurance system, to win a more favorable competitive initiative, out of the "chain of value only in the low end of wandering and controlled by others "business depression. The establishment of a new model, you need raw materials, active pharmaceutical drug promotion and self-discipline, and he also needs all kinds of industrial policy and regulatory science to guide. On the one hand, need the government to support enterprises in the traditional pharmaceutical bulk drug products, upgrade technology and quality standards; the other hand, also need to increase the "high surplus" approval API access and quality, safety and environmental protection system supervision. Focus on the part of the bulk raw material drug production level of the pilot run China National regulatory authorities periodically review and to promote the "Guiding Catalogue of Industrial Structure Adjustment" and "no left to make" effective. At the same time, industry associations should also be released with the operation of the market early warning information on a regular basis, the maximum extent to avoid disorderly competition and duplication, and to guide investment in pharmaceutical science and rational competition.